Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewDihydrexidine hydrochloride
Description: Selective D1-like agonist
Chemical Name: (±)-trans-10,11-Dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine hydrochloride
Purity: ≥98% (HPLC)
Biological Activity for Dihydrexidine hydrochloride
Dihydrexidine hydrochloride is an a potent, full efficacy dopamine D1 agonist which shows no agonist activity at peripheral D2 receptors or adrenoceptors at doses which cause maximal stimulation of D1 sites. The compound appears to be fully bioavailable in brain and exhibits profound antiparkinsonism effects in vivo.
Licensing Information
Sold under license, US Patent 5,047,536
Technical Data for Dihydrexidine hydrochloride
| M. Wt | 303.79 |
| Formula | C17H17NO2.HCl |
| Storage | Desiccate at +4°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 137417-08-4 |
| PubChem ID | 11403931 |
| InChI Key | IJYUPBNUPIRQEP-SATBOSKTSA-N |
| Smiles | OC1=C(O)C=C(CC[C@]3([H])[C@@]([H])2C4=C(C=CC=C4)CN3)C2=C1.Cl |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Dihydrexidine hydrochloride
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| water | 3.04 | 10 | |
| DMSO | 15.19 | 50 |
Preparing Stock Solutions for Dihydrexidine hydrochloride
The following data is based on the product molecular weight 303.79. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.5 mM | 6.58 mL | 32.92 mL | 65.83 mL |
| 2.5 mM | 1.32 mL | 6.58 mL | 13.17 mL |
| 5 mM | 0.66 mL | 3.29 mL | 6.58 mL |
| 25 mM | 0.13 mL | 0.66 mL | 1.32 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for Dihydrexidine hydrochloride
References for Dihydrexidine hydrochloride
References are publications that support the biological activity of the product.
Brewster et al (1990) Trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective DA D1 full agonist. J.Med.Chem. 33 1756 PMID: 1971308
Kholi et al (1993) Dihydrexidine: a new potent peripheral DA D1 receptor agonist. Eur.J.Pharmacol. 235 31 PMID: 8100195
Lovenberg et al (1989) Dihydrexidine, a novel selective high potency, full DA D-1 receptor agonist. Eur.J.Pharmacol. 166 111 PMID: 2572425
Taylor et al (1991) Dihydrexidine, a full DA D1 agonist, reduces MPTP-induced parkinsonism in monkeys. Eur.J.Pharmacol. 199 389 PMID: 1680717
If you know of a relevant reference for Dihydrexidine hydrochloride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Dihydrexidine hydrochloride, Dihydrexidine hydrochloride supplier, Selective, D1-like, agonists, Dopamine, Receptors, D5, dopaminergic, D1, and, 0884, Tocris Bioscience
4 Citations for Dihydrexidine hydrochloride
Citations are publications that use Tocris products. Selected citations for Dihydrexidine hydrochloride include:
Parker and Kooi (2014) Microplate-based screening for small molecule inhibitors of neuropilin-2/vascular endothelial growth factor-C interactions. J Neurosci 453 42525 PMID: 24583243
Urizar et al (2011) CODA-RET reveals functional selectivity as a result of GPCR heteromerization. Anal Biochem 7 624 PMID: 21785426
Gorelova et al (2002) Mechanisms of DA activation of fast-spiking interneurons that exert inhibition in rat prefrontal cortex. J Neurophysiol 88 3150 PMID: 12466437
Smith et al (2005) DArgic stimulation of local protein synthesis enhances surface expression of GluR1 and synaptic transmission in hippocampal neurons. Neuron 45 765 PMID: 15748851
Do you know of a great paper that uses Dihydrexidine hydrochloride from Tocris? Please let us know.
Reviews for Dihydrexidine hydrochloride
There are currently no reviews for this product. Be the first to review Dihydrexidine hydrochloride and earn rewards!
Have you used Dihydrexidine hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.